Regulation of Lipoprotein Transport in Metabolic Syndrome

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to determine whether PPAR-delta agonist (GW5015156)had favorable effect on lipoprotein metabolism.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Western Australia
• Collaborator: National Heart Foundation, Australia

Criteria

Inclusion Criteria:

• Any three of the following:

• Waist circumference > 102 cm

• Triglycerides > 150 mg/dL

• HDL-cholesterol < 40 mg/dL

• Blood glucose > 110 mhg/dL

• Blood pressures > 130/85 mmHg

Exclusion Criteria:

• Triglycerides > 500 mg/dL

• Diabetes mellitus

• CVD

• Consumption of > 30 g alcohol/day

• Use of agents affecting lipid metabolism

• APOE2/E2 genotype

• Creatinemia (> 120 umol/L)

• Hypothyroidism

• Abnormal liver and muscle enzymes